DSM-Firmenich stock gains a U.S. sunscreen growth window

DSM-Firmenich is entering a defined commercial window in the U.S. sunscreen market through its BEMT formulation. The Economic Times reported in an article last updated July 2, 2026, that the company holds exclusive rights to sell the ingredient to U.S. sunscreen manufacturers until early 2028.

BEMT is the common name for bemotrizinol, a chemical sunscreen filter already used in Europe, Asia and Australia. The ingredient absorbs both UVA and UVB radiation and is described in the report as broad spectrum. In the United States, it is expected to appear on ingredient lists under the name Parsol Shield.

Exclusive access supports commercial positioning

The U.S. Food and Drug Administration approval order cited by The Economic Times was scheduled to take effect in August 2026. That timing opens a route for sunscreen manufacturers to add BEMT to products sold in the U.S., although the commercial outcome will depend on product launches, customer adoption and the pace at which manufacturers incorporate the filter into existing formulations.

For DSM-Firmenich, the rights provide a period of protected access to customers rather than a guaranteed revenue stream. The company supplies specialty ingredients across nutrition, health and beauty, so BEMT adds another application with potential exposure to formulation demand. Investors will need to distinguish the strategic opportunity from near-term financial contribution, which depends on volumes, pricing and the speed of retail rollouts.

DSM-Firmenich stock traded at 106.08 euros on Lang & Schwarz at 10:50 CET on Thursday, November 12, 2026.

European investors will continue to assess DSM-Firmenich alongside the AEX market environment.

More news and analyses on DSM-Firmenich stock.